Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P D Nathan

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Therapeutic Advances in Medical Oncology|July 27, 2011
Therapeutic opportunities in noncutaneous melanomaD K Wilkins, P D Nathan
Journal of Bacteriology|November 1, 1992
Regulation of the BamHI restriction-modification system by a small intergenic open reading frame, bamHIC, in both Escherichia coli and Bacillus subtilisC L Ives, P D Nathan, J E Brooks
The Journal of Antibiotics|November 1, 1983
Amino acid precursors of Myxococcus xanthus antibiotic TAS Fytlovitch, P D Nathan, D Zafriri, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|September 10, 2005
Epithelial ovarian cancer: a review of current managementA E Guppy, P D Nathan, G J S Rustin
Immunology Letters|June 1, 1986
Use of monoclonal antibodies reactive with secretory epithelial cells for the immunocytochemical identification of plasma cellsG D Johnson, N R Ling, P D Nathan, et al.
Clinical and Experimental Immunology|June 1, 1988
An analysis of myeloma plasma cell phenotype using antibodies defined at the IIIrd International Workshop on Human Leucocyte Differentiation AntigensN Jackson, N R Ling, J Ball, et al.
Clinical and Experimental Immunology|July 1, 1986
An antigenic study of human plasma cells in normal tissue and in myeloma: identification of a novel plasma cell associated antigenP D Nathan, L Walker, D Hardie, et al.
British Journal of Cancer|August 8, 2013
Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapyN S Vasudev, V Goh, J K Juttla, et al.
Nucleic Acids Research|February 25, 1991
Characterization of the cloned BamHI restriction modification system: its nucleotide sequence, properties of the methylase, and expression in heterologous hostsJ E Brooks, P D Nathan, D Landry, et al.
British Journal of Cancer|April 15, 2010
A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancerG J Rustin, G Shreeves, P D Nathan, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Therapeutic Advances in Medical Oncology|July 27, 2011
Therapeutic opportunities in noncutaneous melanomaD K Wilkins, P D Nathan
Journal of Bacteriology|November 1, 1992
Regulation of the BamHI restriction-modification system by a small intergenic open reading frame, bamHIC, in both Escherichia coli and Bacillus subtilisC L Ives, P D Nathan, J E Brooks
The Journal of Antibiotics|November 1, 1983
Amino acid precursors of Myxococcus xanthus antibiotic TAS Fytlovitch, P D Nathan, D Zafriri, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|September 10, 2005
Epithelial ovarian cancer: a review of current managementA E Guppy, P D Nathan, G J S Rustin
Immunology Letters|June 1, 1986
Use of monoclonal antibodies reactive with secretory epithelial cells for the immunocytochemical identification of plasma cellsG D Johnson, N R Ling, P D Nathan, et al.
Clinical and Experimental Immunology|June 1, 1988
An analysis of myeloma plasma cell phenotype using antibodies defined at the IIIrd International Workshop on Human Leucocyte Differentiation AntigensN Jackson, N R Ling, J Ball, et al.
Clinical and Experimental Immunology|July 1, 1986
An antigenic study of human plasma cells in normal tissue and in myeloma: identification of a novel plasma cell associated antigenP D Nathan, L Walker, D Hardie, et al.
British Journal of Cancer|August 8, 2013
Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapyN S Vasudev, V Goh, J K Juttla, et al.
Nucleic Acids Research|February 25, 1991
Characterization of the cloned BamHI restriction modification system: its nucleotide sequence, properties of the methylase, and expression in heterologous hostsJ E Brooks, P D Nathan, D Landry, et al.
British Journal of Cancer|April 15, 2010
A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancerG J Rustin, G Shreeves, P D Nathan, et al.
Pageof 2